Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH

    AMSTERDAM, Nov. 23 /CNW/ - Kiadis Pharma announces today that there will
be three presentations on its products ATIR and Rhitol in poster sessions at
the 2007 Annual Meeting of the American Society of Hematology (ASH)
December 8-11 in Atlanta, Georgia, USA. Data will be presented from the
companies ongoing clinical study on ATIR by its principal investigator Dr.
Denis Claude Roy, who also presents data on the functionality of Rhitol. In
addition, Dr. Stephan Mielke presents data from an ATIR study conducted at the
    ATIR: presentation of clinical phase I/II study on mismatched
transplantations by Dr. Denis-Claude Roy
    Title poster: "Phase I/II clinical trial of Haplotype Mismatched
Myeloablative Stem Cell Transplantation: Higher doses of Donor Lymphocyte
Infusions depleted of Alloreactive Cells using ATIR may improve outcome
without causing GvHD

    - Abstract No. 2976; Poster 2976, Board No. 195-III (10 December,5-7 pm)

    Dr. Denis Claude Roy head of Stem Cell Transplantation Unit, Hospital
Maisonneuve-Rosemont, Montreal, Canada: "Our results indicate that the
post-transplant infusion of a ATIR-PDT treated DLI is feasible, does not
induce acute GVHD, and suggests a clinical benefit for patients receiving the
highest DLI doses to accelerate T cell reconstitution. This PDT strategy
represents an appealing alternative for older patients and those at high risk
for GVHD"
    Rhitol: presentation on functionality of Rhitol in chronic GvHD by Dr.
Denis-Claude Roy
    Title poster: " anti-Chronic Graft Versus Host Disease activity through a
regulatory T Cell dependent mechanism after photodynamic therapy.

    - Abstract No. 3280; Poster 3280; Board No. 499-III (10 December,5-7 pm)

    Dr. Denis-Claude Roy head of Stem Cell Transplantation Unit, Hospital
Maisonneuve-Rosemont, Montreal, Canada: "our results demonstrate that TH9402
PDT not only eliminates activated T cells, but preserves Tregs, with the
functional ability to inhibit residual alloreactive cGVHD cells. This
inhibitory effect requires live effector Tregs, secretion of IL-10 and
TGF-I(2) expression. With such dual effector mechanisms, photopheresis using
TH9402 should translate into improved treatment efficacy and enhanced quality
of life for patients with chronic GVHD"
    Presentation of independent NIH study of Kiadis Pharma product ATIR Dr.
Stephan Mielke
    Title poster: "Successful Translation of a GMP-Based, Clinical Scale
Selective Allodepletion Approach for Matched Donor-Recipient Pairs from

    - Abstract No. 3279; Poster 3279, board No. 499-III (10 December, 5-7 pm)

    For the complete press release go to:

    (Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists)

For further information:

For further information: Kiadis Pharma B.V., Eefje Simpelaar,, +31-208884815, +31-610829344

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890